Bibliografia

1. Furlanello F, Bertoldi A, Fernando F, Biffi A. Competitive athletes with arrhythmias. Classification, evaluation and treatment. In: Bayes de Luna A, Furlanello F, Maron BJ, Zipes DP, eds. Arrhythmias and sudden death in athletes. Dordrecht: Kluwer Academic Publishers; 2000: 89-105.

2. Al Sheikh T, Zipes D. Guidelines for competitive athletes with arrhythmias. In: Bayes de Luna A, Furlanello F, Maron BJ, Zipes DP, eds. Arrhythmias and sudden death in athletes. Dordrecht: Kluwer Academic Publishers; 2000: 119-51.

3. Thiene G, Basso C, Corrado D. Pathology of sudden death in young athletes: European experience. In: Bayes de Luna A, Furlanello F, Maron BJ, Zipes DP, eds. Arrhytmias and sudden death in athletes. Dordrecht: Kluwer Academic Publishers; 2000: 49-69.

4. Furlanello F, Fernando F, Galassi A, Bertoldi A. Ventricular arrhythmias in apparently healthy athletes. In: Malik M, ed. Risk of arrhythmia and sudden death. London: BMJ Books; 2001: 316-24.

5. Maron BJ. The paradox of exercise. N Engl J Med 2000; 343(19): 1409-11.

6. Bertoldi A, Furlanello F, Fernando F et al. Risk stratification in elite athletes with arrhythmias. In: Furlanello F, Bertoldi A, Cappato R, eds. Proceedings of The New Frontiers of Arrhythmias 2002. GIAC 2002; 5( suppl. 1): 218-9.

7. Maron BJ. Cardiovascular causes and pathology of sudden death in athletes: the American experience. In: Bayes de Luna A, Furlanello F, Maron BJ, Zipes DP, eds. Arrhythmias and sudden death in athletes. Dordrecht: Kluwer Academic Publishers; 2000: 31-48.

8. Capua G. Le attività di prevenzione e controllo del doping nel calcio. Attività fisico sportiva: aspetti fisiopatologici. Atti del Congresso dell’Associazione nazionale specialisti in medicina dello sport dell’Università “G. D’Annunzio”; 2002: 161-73.

9. Kloner AR. Illicit drug use in the athlete as a contributor to cardiac events. In: Estes NAM, Salem DN, Wang PJ, eds. Sudden cardiac death in the athlete. Armonk, NY: Futura Publishing CO., Inc.; 1998: 441-51.

10. Clarckson PM, Thompson HS. Drug and sport. Research findings and limitations. Sports Med 1997; 24(6): 366-84.

11. Bauman JL, Grawe JJ, Winecoff AP et al. Cocaine-related sudden cardiac death: a hypothesis correlating basic science and clinical observations. J Clin Pharmacol 1994; 34: 902-11.

12. Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: an analysis and review of the literature. J Emerg Med 1992; 10: 169-77.

13. Sloan MA, Mattioni TA. Concurrent myocardial and cerebral infarction after intranasal cocaine use. Stroke 1992; 23: 427-30.

14. Billman GE. Cocaine: a review of its toxic actions on cardiac function. Crit Rev Toxicol 1995; 25: 113-32.

15. Hale SL, Lehmann MH, Kloner RA. Electrocardiographic abnormalities after acute administration of cocaine in the rat. Am J Cardiol 1989; 63: 1529-30.

16. Carson P, Oldroyd K, Phadke K. Myocardial infarction due to amphetamine. Br Med J Clin Res Ed 1987; 294: 1525-6.

17. Yesalis CE, Bahrke MS. Doping among adolescent athletes. Pract Res Clin Endocrinol Metab 2000; 14(1): 25-35.

18. Nilsson S, Biagi M, Marklund B et al. The prevalence of use of androgenic steroids by adolescents in a county of Sweden. Eur J Public Health 2001; 11(2): 195-7.

19. Benzi G, Ceci A. Are the IOC lists of forbidden drugs suitable to prevent doping? The nandrolone lesson. In: Atti del Convegno di aggiornamento in cardiologia dello sport. In: D. Bracchetti. Bologna; 2002: 113-6.

20. McCarthy K, Tang A, Dalrymple-Hay M. Ventricular thrombosis and systemic embolism in bodybuilders: etiology and management. Ann Thorac Surg 2000; 70(2): 658-60.

21. Welder AA, Melchert RB. Cardiotoxic effects of cocaine and anabolic-androgenic steroids in the athlete. J Pharmacol Toxicol Methods 1993; 29(2): 61-8.

22. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 1995; 27(9): 1252-62.

23. Appleby M, Fisher M, Martin M. Myocardial infarction, hyperkalaemia and ventricular tachycardia in a young male body-builder. Int J Cardiol 1994; 44(2): 171-4.

24. Frankle MA, Eichberg R, Zachariah SB. Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehabil 1988; 69(8): 632-3.

25. Dickerman RD, McConathy WJ, Zachariah NY. Testosterone, sex hormone-binding globulin, lipoproteins, and vascular disease risk. J Cardiovasc Risk 1997; 4(5-6): 363-6.

26. Lenders JW, Demacker PN, Vos JA. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body-builders. J Sports Med 1988; 9(1): 19-23.

27. Strauss RH, Yesalis CE. Anabolic steroids in the athlete. Annu Rev Med 1991; 42: 449-57.

28. Laseter JT, Russel JA. Anabolic steroids induced tendon pathology: a review of the literature. Med Sci Sports Exerc 1991; 23(1): 1-3.

29. Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999; 17(5):851-7.

30. Green GA, Catlin DH, Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med 2001; 11(4): 254-9.

31. Congeni J, Miller S. Supplements and drugs used to enhance athletic performance. Pediatr Clin North Am 2002; 49(2): 435-61.

32. Berges R, Segura J, Ventura R et al. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Clin Chem 2000; 46(9): 1365-75.

33. Carlsen KH, Hem E, Stensrud T et al. Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes. Respir Med 2001; 95(7): 571-6.

34. Botrè F. Il laboratorio antidoping del CIO di Roma. Attività fisico sportiva: aspetti fisiopatologici Atti del Congresso dell’Associazione nazionale specialisti in medicina dello sport dell’Università “G. D’Annunzio”; 2002: 128-38.

35. Jlekmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 2000; 1(1): 11-31.

36. Cervo L. I danni delle sostanze dopanti. In: Atti del Convegno di aggiornamento in cardiologia dello sport. In: D. Bracchetti. Bologna; 2002: 117-20.

37. Wilber RL. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med 2002; 32(2): 125-42.

38. Farzati B, Il doping ematico: una breve rassegna. Attività fisico sportiva: aspetti fisiopatologici. Atti del Congresso dell’Associazione nazionale specialisti in medicina dello sport dell’Università “G. D’Annunzio”; 2002: 117-27.

39. Schumacher YO, Grathwohl D, Barturen JM et al. Haemoglobin, haematocrit and red blood in elite cyclists. Are the control values for blood testing valid? Int J Sports Med 2000; 21(5): 380-5.

40. Parisotto R, Wu M, Ashenden MJ et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 2001; 86(2): 128-37.

41. Ekblom BT. Blood boosting and sport. Pract Res Clin Endocrinol Metab 2000; 14(1): 89-98.

42. Bellastella A, Pisano G, Solimeno S et al. Il doping: aspetti farmacologici, GH ed IGF-1. Atti del Congresso dell’Associazione nazionale specialisti medicina dello sport dell’Università “G. D’Annunzio”; 2002; 108-16.

43. Pirnary F. Doping in sports. Rev Med Liege 2001; 56: 265-8.

44. Ehrnborg C, Bengtsson BA, Rosen T. Growth hormone abuse. Baillieres Bes Pract Res Clin Endocrinol Metab 2000; 14(1): 71-7.

45. Karila T, Koistinen H, Seppala M et al. Growth hormone induced increase in serum IGFBP-3 level is reversed by anabolic steroids in substance abusing power athletes. Clin Endocrinol (Oxf) 1998; 49: 459-63.

46. Wallace JD, Cuneo RC, Baxter R et al. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J Clin Endocrinol Metab 1999; 84(10): 3591-601.

47. Armanini D, Faggian D, Scaroni C. Growth hormone and insulin-like growth factor I in a Sydney Olympic gold medallist. Br J Sports Med 2002; 36(2): 148-9.

48. Takala J, Ruokonen E, Webster NR et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 342: 785-92.

49. Jenkins PJ. Growth hormone and exercise: physiology, use and abuse. Growth Horm IGF Res 2001; 11 (Suppl A): S71-7.

50. De Paolo EF, Gatti R, Lancerin F et al. Correlations of growth hormone (GH) - and insulin-like growth factor I (IGF-I): effects of exercise and abuse by athletes. Clin Chim Acta 2001; 305(1-2): 1-17.